Randomised clinical trial: high‐dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease

Abstract

SummaryBackgroundFatigue is a burdensome symptom for patients with inflammatory bowel disease (IBD). Few pharmacological interventions have documented effect on fatigue in patients with IBD. A pilot study indicated a 20‐day effect  with high‐dose thiamine.AimsTo investigate the effect and safety of high‐dose oral thiamine (600‐1800 mg/d) based on gender and weight on chronic fatigue in patients with quiescent IBD.MethodsThis was a randomised, double‐blinded, placebo‐controlled crossover trial. Patients had quiescent IBD, severe chronic fatigue and no other explanation for fatigue. Patients were allocated 1:1 to either 1) high‐dose oral thiamine for 4 weeks, 4 weeks of washout, 4 weeks of oral placebo or 2) oral placebo for 4 weeks, 4 weeks of washout, 4 weeks of high‐dose oral thiamine. Fatigue was measured using the Inflammatory Bowel Disease‐Fatigue Questionnaire. The primary outcome was improvement (≥3 points) of fatigue after 4 weeks on thiamine.ResultsForty patients were enrolled between November 2018 and October 2019. Crossover analysis showed a mean reduction of 4.5 points (95% CI 2.6‐6.2) in fatigue after thiamine compared with a mean increase of 0.75 point (95% CI −1.3‐2.8; P = 0.0003) after placebo. Furthermore, 55% of group 1 and 75% of group 2 showed an improvement ≥ 3 points while on thiamine compared with 25% of group 1 and 35% of group 2 while on placebo. Only mild side effects were detected.ConclusionWe showed a significant beneficial effect of high‐dose oral thiamine on chronic fatigue in IBD. The treatment was well tolerated.Trial registration: NCT03634735.